Shire has just announced a new partnership with the Cystic Fibrosis Foundation to develop technology that can maintain lung function and protect against respiratory infections.
PulmoFlow Inc’s Kitabis Pak, a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer, has been approved to treat cystic fibrosis.
Gone are the days when an RT had to use muscle alone to clear lung secretions. Technology has made this more efficient, effective, and patient friendly.
Researchers have shown for the first time how bacteria can grow directly in the lungs of cystic fibrosis patients, which has provided tremendous insights into bacteria behavior and growth in chronic infections.
Researchers have discovered an inhibitor for an enzyme called Sphingomyelin phosphodiesterase C (SMaseC) which is produced by the S. aureus bacterium and may harm the health of CF patients.
A team of international researchers found that the immunological cell surface molecule HLA-DQ is reduced or absent in many cystic fibrosis patients.
Scientists now have shown that many of the adult patients with cystic fibrosis in addition lack a cell surface molecule, important for immune defence.
Researchers hope the drug sildenafil, as well as a cocktail of over-the-counter antioxidants, will help them identify the root of the blood vessel dysfunction that makes exercise difficult for CF patients.
New research shows that cystic fibrosis causes a specific defect in the lungs’ mucus process.
Vertex Pharmaceuticals Inc says results from two Phase 3 studies of its lumacaftor-ivacaftor drug combination showed statistically significant improvements in lung function (ppFEV1) in cystic fibrosis patients (12+) who have two copies of the F508del mutation.